Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
Mycoses. 2023 Mar;66(3):196-201. doi: 10.1111/myc.13541. Epub 2022 Nov 2.
Studies comparing gradient diffusion strips (GDSs) and the EUCAST E.Def 9.4 microdilution method are scarce, thwarted by a low number of isolates, and restricted to selected antifungal agents.
We evaluated the performance of GDSs to detect azole resistance in A. fumigatus, including cryptic species.
PATIENTS/METHODS: A. fumigatus sensu stricto (n = 89) and cryptic species (n = 52) were classified as susceptible or resistant to itraconazole, voriconazole, posaconazole and isavuconazole (EUCAST E.Def 9.4; clinical breakpoints v10). A. fumigatus sensu stricto azole-resistant isolates had the following cyp51A gene mutations: TR -L98H (n = 24), G54R (n = 5), TR -Y121F-T289A (n = 1), F46Y-M172V-N248T-D255E-E427K (n = 1), F165L (n = 1) and cyp51A gene wild type (n = 3). GDSs (ETEST®, bioMèrieux, Marcy-l'Etoile, France and Liofilchem®, Roseto degli Abruzzi, Italy) MICs were obtained by following the manufacturer's guidelines.
For A. fumigatus sensu stricto, itraconazole MICs >1.5 mg/L, voriconazole >0.38 mg/L, posaconazole >0.75 mg/L, and isavuconazole >0.5 mg/L correctly separated resistant from susceptible isolates with two exceptions. Considering the aforementioned cut-off MICs, sensitivity/specificity values of GDSs to detect azole resistance were: itraconazole (97%/100%), voriconazole (97%/100%), posaconazole (97%/100%) and isavuconazole (93.3%/100%). For cryptic species isolates, voriconazole MICs >1 mg/L and isavuconazole >0.75 mg/L separated resistant isolates from susceptible isolates with 15 and 27 exceptions, respectively. Considering the aforementioned cut-off MICs, sensitivity/specificity values were as follows: voriconazole (68.1%/100%) and isavuconazole (25%/100%). For itraconazole and posaconazole, it was not possible to establish cut-off values.
We set tentative cut-off MIC values to correctly spot resistant Aspergillus fumigatus sensu stricto isolates using GDSs. The performance against cryptic species was poor.
比较梯度扩散条(GDS)和 EUCAST E.Def 9.4 微量稀释法的研究很少,这是由于分离株数量较少,并且仅限于选择抗真菌药物。
我们评估了 GDS 检测烟曲霉中唑类耐药性的性能,包括隐种。
患者/方法:烟曲霉严格意义上的(n=89)和隐种(n=52)被分类为对伊曲康唑、伏立康唑、泊沙康唑和伊沙康唑敏感或耐药(EUCAST E.Def 9.4;临床折点 v10)。烟曲霉严格意义上的唑类耐药分离株具有以下 cyp51A 基因突变:TR-L98H(n=24)、G54R(n=5)、TR-Y121F-T289A(n=1)、F46Y-M172V-N248T-D255E-E427K(n=1)、F165L(n=1)和 cyp51A 基因野生型(n=3)。按照制造商的指南,通过 GDS(ETEST®,bioMèrieux,Marcy-l'Etoile,法国和 Liofilchem®,Roseto degli Abruzzi,意大利)获得梯度扩散条 MICs。
对于烟曲霉严格意义上的,伊曲康唑 MICs >1.5mg/L、伏立康唑 >0.38mg/L、泊沙康唑 >0.75mg/L 和伊沙康唑 >0.5mg/L 正确地区分了耐药和敏感分离株,但有两个例外。考虑到上述 MIC 截止值,GDS 检测唑类耐药性的敏感性/特异性值为:伊曲康唑(97%/100%)、伏立康唑(97%/100%)、泊沙康唑(97%/100%)和伊沙康唑(93.3%/100%)。对于隐种分离株,伏立康唑 MICs >1mg/L 和伊沙康唑 >0.75mg/L 分别分离了 15 和 27 个耐药分离株和敏感分离株,但有例外。考虑到上述 MIC 截止值,敏感性/特异性值如下:伏立康唑(68.1%/100%)和伊沙康唑(25%/100%)。对于伊曲康唑和泊沙康唑,无法确定截止值。
我们设定了暂定的 MIC 截止值,以使用 GDS 正确识别烟曲霉严格意义上的耐药分离株。对隐种的性能较差。